DK3359660T3 - Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene - Google Patents
Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene Download PDFInfo
- Publication number
- DK3359660T3 DK3359660T3 DK16785045.2T DK16785045T DK3359660T3 DK 3359660 T3 DK3359660 T3 DK 3359660T3 DK 16785045 T DK16785045 T DK 16785045T DK 3359660 T3 DK3359660 T3 DK 3359660T3
- Authority
- DK
- Denmark
- Prior art keywords
- human
- constant region
- cell receptor
- region gene
- recognition sequences
- Prior art date
Links
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 title 1
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562237382P | 2015-10-05 | 2015-10-05 | |
US201662297445P | 2016-02-19 | 2016-02-19 | |
PCT/US2016/055472 WO2017062439A1 (en) | 2015-10-05 | 2016-10-05 | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3359660T3 true DK3359660T3 (en) | 2020-02-17 |
Family
ID=57184827
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16785045.2T DK3359660T3 (en) | 2015-10-05 | 2016-10-05 | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
DK19212310.7T DK3680329T3 (da) | 2015-10-05 | 2016-10-05 | Modificerede meganukleaser med genkendelsesekvenser der findes i genet for den humane t-cellereceptor-alpha-konstantregion |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK19212310.7T DK3680329T3 (da) | 2015-10-05 | 2016-10-05 | Modificerede meganukleaser med genkendelsesekvenser der findes i genet for den humane t-cellereceptor-alpha-konstantregion |
Country Status (8)
Country | Link |
---|---|
US (3) | US10799535B2 (da) |
EP (3) | EP3680329B1 (da) |
JP (3) | JP6929837B2 (da) |
AU (3) | AU2016333886B2 (da) |
CA (1) | CA3001008A1 (da) |
DK (2) | DK3359660T3 (da) |
ES (2) | ES2883116T3 (da) |
WO (1) | WO2017062439A1 (da) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3756682B8 (en) | 2015-10-05 | 2022-04-27 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
DK3359660T3 (en) | 2015-10-05 | 2020-02-17 | Prec Biosciences Inc | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
US20190161530A1 (en) * | 2016-04-07 | 2019-05-30 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
BR112018071199A2 (pt) | 2016-04-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | célula t, população isolada de células t, composição farmacêutica, método de tratamento, método para gerar uma célula t, vetor, célula tronco |
WO2019005957A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE |
WO2019070856A1 (en) * | 2017-10-03 | 2019-04-11 | Precision Biosciences, Inc. | MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY MODIFIED CELLS |
KR102503130B1 (ko) * | 2017-10-27 | 2023-02-24 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 내인성 t 세포 수용체의 표적화된 대체 |
CA3081320A1 (en) | 2017-10-30 | 2019-05-09 | Pact Pharma, Inc. | Primary cell gene editing |
KR20200138334A (ko) | 2018-04-02 | 2020-12-09 | 팩트 파마, 인크. | 펩티드-MHC comPACT |
AU2019252527B2 (en) | 2018-04-12 | 2024-02-22 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
AU2020221229A1 (en) | 2019-02-12 | 2021-09-02 | Adoc Ssf, Llc | Compositions and methods for identification of antigen specific T cells |
WO2020205759A1 (en) * | 2019-03-29 | 2020-10-08 | Pact Pharma, Inc. | Personalized neoantigen-specific adoptive cell therapies |
CA3135799A1 (en) | 2019-04-03 | 2020-10-08 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
KR20220005555A (ko) | 2019-05-07 | 2022-01-13 | 프리시젼 바이오사이언시스 인코포레이티드 | 인식 서열에 대한 조작된 메가뉴클레아제의 최적화 |
US20220273715A1 (en) | 2019-07-25 | 2022-09-01 | Precision Biosciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
AU2020333851A1 (en) | 2019-08-20 | 2022-03-31 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
CA3150095A1 (en) * | 2019-09-06 | 2021-03-11 | Shirley O'dea | IMMUNE CELL ENGINEERING FOR EX VIVO CELLULAR THERAPY APPLICATIONS |
WO2021087305A1 (en) | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
CA3159557A1 (en) * | 2019-11-05 | 2021-05-14 | Lonza Walkersville, Inc. | Allogeneic t-cells and methods for production thereof |
WO2021113543A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells |
WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
EP4192875A1 (en) | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
EP4284823A1 (en) | 2021-01-28 | 2023-12-06 | Precision BioSciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
EP4326861A1 (en) * | 2021-04-22 | 2024-02-28 | Precision Biosciences, Inc. | Engineered meganucleases that target human mitochondrial genomes |
WO2023064872A1 (en) | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
WO2023133525A1 (en) | 2022-01-07 | 2023-07-13 | Precision Biosciences, Inc. | Optimized polynucleotides for protein expression |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
US20100151556A1 (en) | 2002-03-15 | 2010-06-17 | Cellectis | Hybrid and single chain meganucleases and use thereof |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
JP5937292B2 (ja) | 2005-10-18 | 2016-06-22 | デューク大学 | 配列特異性およびdna−結合親和度が変更された、合理設計メガヌクレアーゼ |
WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
DK2215223T3 (da) | 2007-10-31 | 2013-07-22 | Prec Biosciences Inc | Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser |
EP2329017A2 (en) | 2008-08-04 | 2011-06-08 | Cellectis | Novel method to generate meganucleases with altered characteristics |
EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
EP2596011B1 (en) * | 2010-07-21 | 2018-10-03 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a hla locus |
DK3489366T3 (da) | 2011-06-01 | 2020-02-24 | Prec Biosciences Inc | Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener |
WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
WO2013176916A1 (en) | 2012-05-25 | 2013-11-28 | Roman Galetto | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
KR20140019635A (ko) | 2012-08-06 | 2014-02-17 | 엘지이노텍 주식회사 | 발광 소자 및 발광 소자 패키지 |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
CA2913872C (en) | 2013-05-31 | 2022-01-18 | Cellectis | A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof |
CA2913871C (en) | 2013-05-31 | 2021-07-13 | Cellectis | A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof |
ES2881473T3 (es) | 2013-10-17 | 2021-11-29 | Sangamo Therapeutics Inc | Métodos de suministro y composiciones para la modificación por ingeniería genética del genoma mediada por nucleasas |
DK3105317T3 (da) | 2014-02-14 | 2019-01-14 | Cellectis | Celler til immunterapi, som er genmanipuleret til at være rettet mod antigen både på immunceller og patologiske celler |
KR102228828B1 (ko) * | 2014-03-11 | 2021-03-16 | 셀렉티스 | 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법 |
JP2017512767A (ja) * | 2014-03-12 | 2017-05-25 | プレシジョン バイオサイエンシズ,インク. | 改変ヌクレアーゼを用いたジストロフィン遺伝子エクソンの欠失 |
GB2540694A (en) | 2014-04-29 | 2017-01-25 | Seattle Children's Hospital (Dba Seattle Children's Res Institute) | CCR5 disruption of cells expressing anti-hiv chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies |
CN113215196A (zh) | 2014-06-06 | 2021-08-06 | 瑞泽恩制药公司 | 用于修饰所靶向基因座的方法和组合物 |
BR112017005245A2 (pt) | 2014-09-19 | 2017-12-12 | Regeneron Pharma | animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. |
AU2015339744B2 (en) | 2014-10-31 | 2021-03-25 | The Trustees Of The University Of Pennsylvania | Altering gene expression in CART cells and uses thereof |
BR112017020750A2 (pt) | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
CA2991301A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
EP3756682B8 (en) | 2015-10-05 | 2022-04-27 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
DK3359660T3 (en) | 2015-10-05 | 2020-02-17 | Prec Biosciences Inc | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
WO2017070429A1 (en) | 2015-10-22 | 2017-04-27 | Regents Of The University Of Minnesota | Methods involving editing polynucleotides that encode t cell receptor |
CA3009637A1 (en) * | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
WO2017156484A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Genome edited immune effector cells |
BR112018071199A2 (pt) | 2016-04-15 | 2019-02-12 | Memorial Sloan Kettering Cancer Center | célula t, população isolada de células t, composição farmacêutica, método de tratamento, método para gerar uma célula t, vetor, célula tronco |
WO2019005957A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE |
AU2019252527B2 (en) | 2018-04-12 | 2024-02-22 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
-
2016
- 2016-10-05 DK DK16785045.2T patent/DK3359660T3/da active
- 2016-10-05 EP EP19212310.7A patent/EP3680329B1/en active Active
- 2016-10-05 DK DK19212310.7T patent/DK3680329T3/da active
- 2016-10-05 ES ES19212310T patent/ES2883116T3/es active Active
- 2016-10-05 WO PCT/US2016/055472 patent/WO2017062439A1/en active Application Filing
- 2016-10-05 AU AU2016333886A patent/AU2016333886B2/en active Active
- 2016-10-05 EP EP16785045.2A patent/EP3359660B1/en active Active
- 2016-10-05 ES ES16785045T patent/ES2768984T3/es active Active
- 2016-10-05 CA CA3001008A patent/CA3001008A1/en active Pending
- 2016-10-05 JP JP2018517357A patent/JP6929837B2/ja active Active
- 2016-10-05 US US15/766,290 patent/US10799535B2/en active Active
- 2016-10-05 EP EP21177206.6A patent/EP3940070A1/en active Pending
-
2020
- 2020-09-09 US US17/016,056 patent/US11266693B2/en active Active
- 2020-12-15 AU AU2020289750A patent/AU2020289750B2/en active Active
-
2021
- 2021-08-11 JP JP2021131109A patent/JP2022000019A/ja active Pending
-
2022
- 2022-01-31 US US17/589,594 patent/US20220152112A1/en active Pending
-
2023
- 2023-04-03 AU AU2023202022A patent/AU2023202022A1/en active Pending
- 2023-08-18 JP JP2023133416A patent/JP2023175698A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2016333886A1 (en) | 2018-05-10 |
WO2017062439A9 (en) | 2018-11-29 |
JP6929837B2 (ja) | 2021-09-15 |
JP2023175698A (ja) | 2023-12-12 |
CA3001008A1 (en) | 2017-04-13 |
JP2018536390A (ja) | 2018-12-13 |
JP2022000019A (ja) | 2022-01-04 |
AU2020289750B2 (en) | 2023-01-12 |
AU2020289750A1 (en) | 2021-01-21 |
EP3680329B1 (en) | 2021-06-09 |
US20180289741A1 (en) | 2018-10-11 |
EP3940070A1 (en) | 2022-01-19 |
EP3680329A1 (en) | 2020-07-15 |
ES2768984T3 (es) | 2020-06-24 |
EP3359660A1 (en) | 2018-08-15 |
DK3680329T3 (da) | 2021-08-23 |
US20210052650A1 (en) | 2021-02-25 |
US11266693B2 (en) | 2022-03-08 |
WO2017062439A1 (en) | 2017-04-13 |
ES2883116T3 (es) | 2021-12-07 |
US10799535B2 (en) | 2020-10-13 |
AU2016333886A9 (en) | 2019-08-01 |
US20220152112A1 (en) | 2022-05-19 |
EP3359660B1 (en) | 2019-12-04 |
AU2023202022A1 (en) | 2023-06-15 |
AU2016333886B2 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3359660T3 (en) | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene | |
IL287319A (en) | Genetically modified cells containing a modified human t cell receptor alpha constant region gene | |
IL267129A (en) | New T-cell receptors and immunotherapy using them | |
HK1243332A1 (zh) | 改變在修飾的t細胞中的基因表達及其用途 | |
IL274505A (en) | Transgenic T cell receptors and immunotherapy using them | |
SG11201803493UA (en) | Genetically modified cells and uses thereof | |
EP3197501C0 (en) | BIOLOGICAL MATERIALS AND USES THEREOF | |
PT3122769T (pt) | Polipéptidos, células e métodos que envolvem cd16 manipulado | |
EP3612205C0 (en) | MODIFIED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE PCSK9 GENE | |
GB201602974D0 (en) | Engineered cells & methods (1) | |
IL259202A (en) | Modified immune cells and their use | |
HUE049806T2 (hu) | Módosított gazdasejtek és alkalmazásaik | |
GB201414021D0 (en) | Biological materials and uses thereof | |
GB201410226D0 (en) | Methods and arrays for use in the same | |
GB201500500D0 (en) | Biological materials and therapeutic uses thereof | |
PL3250234T3 (pl) | Rekombinowany mdv1 i jego zastosowania | |
SG11201610918RA (en) | Peptides and uses thereof | |
GB201413810D0 (en) | The sun lounger cocoon | |
IL267131A (en) | Novel t cell receptors and immune therapy using the same | |
IL264855B1 (en) | T-cell receptors and immunotherapy using them | |
SG11202003404UA (en) | Novel engineered t cell receptors and immune therapy using the same | |
GB201622225D0 (en) | Modified host cells and uses thereof | |
EP3201224C0 (en) | HUMAN G PROTEIN ALPHA GXI1 SUBUNIT WITH AT LEAST ONE MUTATED AMINO ACID RESIDUE | |
GB201616232D0 (en) | Novel cell line and uses thereof | |
GB201517184D0 (en) | Biological materials and uses thereof |